Biocon Secures US FDA Approval for Fifth Oncology Biosimilar, Pebrilzo
Biocon's Pebrilzo, a Perjeta biosimilar for HER2-positive breast cancer, wins U.S. FDA approval as its fifth oncology biosimilar, with a Q3 2028 U.S. launc
Research Desk
Biocon Limited (BSE: 532523; NSE: BIOCON) announced that the U.S. Food and Drug Administration has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab).
The monoclonal antibody is used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells.
Fifth Oncology Biosimilar Approval
With the approval, Biocon's oncology portfolio in the United States now totals five biosimilar therapies for cancer.
Shreehas Tambe, CEO and Managing Director of Biocon Limited, said the approval marks another significant milestone in the company's journey to expand access to high-quality biosimilars.
He noted that for patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond physical challenges, often placing considerable financial strain on patients and their families.
As the company's fifth oncology biosimilar to receive U.S. FDA approval, he said, Pebrilzo strengthens its anti-cancer portfolio and advances its commitment to expanding access to high-quality, affordable biologic medicines.
Commercial Launch Timeline and Genentech Agreement
Alongside the approval announcement, Biocon disclosed a global settlement and license agreement with Genentech securing the earliest licensed launch date for Pebrilzo in the United States in the third quarter of calendar year 2028.
The company framed the approval as an important step toward broadening treatment options for patients with HER2-positive breast cancer in the United States, subject to the anticipated commercial launch timeline.
Positive Opinion in Europe
The U.S. approval follows regulatory movement in Europe.
In September, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion recommending the granting of a marketing authorization for Biocon's pertuzumab biosimilar as a 420 mg/14 mL concentrate solution for infusion under the brand name Pebrilzo for the treatment of HER2-positive breast cancer across multiple disease stages in Europe.
Evidence Basis for Approval
The FDA approval was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data.
According to the company, the data confirmed that Pebrilzo is highly similar to the reference biologic Perjeta, with no clinically meaningful differences in quality, safety, efficacy, and immunogenicity.
Approved Indications and Safety Information
Pebrilzo is a HER2/neu receptor antagonist indicated for use in metastatic breast cancer in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
It is also indicated for early breast cancer in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, either greater than 2 cm in diameter or node positive, as part of a complete treatment regimen, and for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
The drug carries warnings for left ventricular dysfunction and embryo-fetal toxicity.
Pebrilzo can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction and congestive heart failure, and cardiac function must be evaluated prior to and during treatment, with discontinuation required for a confirmed clinically significant decrease in left ventricular function.
Exposure to Pebrilzo can cause embryo-fetal death and birth defects, and patients are to be advised of these risks and the need for effective contraception. The drug is contraindicated in patients with known hypersensitivity to pertuzumab or any of its excipients.
Existing Portfolio and Growing Pipeline
Pebrilzo will join an established portfolio of oncology therapies that includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb), and Aukelso (denosumab-kyqq).
The company's growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
Disease Context
HER2-positive breast cancer is a subtype characterized by HER2 protein overexpression and/or HER2 gene amplification, which drives aggressive tumor growth.
Approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026, of whom about 20 percent will have HER2-positive breast cancer.
More broadly, one in eight women is expected to be diagnosed with breast cancer during her lifetime, which the company cites as underscoring the ongoing need for treatment options in this area.
Tracked in the database
FDA Approval / Regulatory News · North America
FDA Approval / Regulatory News
North America
Chemical
16 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.